BPC-157: Research Overview

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — whose sequence is derived from a protective protein found in human gastric juice. "BPC" stands for Body Protection Compound, a name reflecting the research program that produced it: a decades-long investigation, led by the laboratory of Predrag Sikiric at the University of Zagreb, into how gastric-derived peptides influence tissue protection and repair. With several hundred published preclinical studies, BPC-157 is among the most researched repair peptides in the literature — and also one whose evidence base is entirely preclinical, a distinction this overview addresses directly.

How BPC-157 works in research models

No single receptor has been established for BPC-157; the literature instead describes a network of signaling effects observed across cell and animal models:

• Angiogenesis signaling: studies report BPC-157 influencing vascular endothelial growth factor (VEGF) pathways and VEGFR2 activation, supporting new-vessel formation in injured-tissue models — a proposed basis for its repair effects in poorly vascularized tissues like tendon.
• Nitric-oxide system interaction: a body of work describes BPC-157 modulating the NO pathway, counteracting both NO-blockade and NO-overproduction states in animal models — unusual bidirectional behavior that remains an active research question.
• Cell-migration pathways: in tendon fibroblast models, research describes BPC-157 activating the FAK–paxillin pathway, promoting the migration of repair cells into damaged matrix.
• Growth-hormone-receptor expression: published cell work (Chang and colleagues, 2014) reported BPC-157 increasing growth-hormone-receptor expression in tendon fibroblasts, a proposed mechanism for enhanced repair signaling in those models.

Research timeline

The Sikiric laboratory's program began in the 1990s with gastric-protection research and expanded into systematic studies of tendon, muscle, bone, gastrointestinal, and nervous-system models through the 2000s–2020s. Independent groups have since published confirmatory and mechanistic work, particularly on tendon fibroblasts and angiogenesis. Despite the volume of preclinical literature, no completed, published randomized controlled human trials exist — BPC-157 remains a preclinical research compound.

Key published findings

• Tendon and ligament models: rat studies of transected Achilles tendon reported accelerated functional and histological recovery markers under research protocols; tendon-to-bone healing models reported improved attachment endpoints.
• Gastrointestinal models: consistent with its origin, a large literature describes protective effects in chemically induced GI-lesion, fistula, and inflammatory-bowel models in animals.
• Muscle and systemic injury models: animal studies report improved recovery markers in muscle crush, transection, and systemic-injury models.
• CNS-interaction research: studies have examined BPC-157's interactions with dopaminergic and serotonergic systems in animal models, including counteraction of agent-induced disturbances — an emerging mechanistic branch.

Context among related compounds

BPC-157 anchors the repair-peptide category. Its closest research partner is TB-500 — where BPC-157 research emphasizes growth-factor and angiogenesis signaling, TB-500 research emphasizes actin regulation and cell migration. The two address complementary bottlenecks in repair biology, which is why both appear together in the KLOW research blend. GHK-Cu covers the matrix-remodeling dimension from the copper-peptide side.

What researchers examine

Active research questions include receptor identification (the field's largest open question), angiogenesis kinetics in ischemic-tissue models, tendon-fibroblast signaling cascades, NO-system bidirectionality, and GI-barrier protection mechanisms. Researchers value BPC-157 for the breadth of published models available to anchor new experimental designs.

Frequently asked research questions

Is there human clinical data on BPC-157?

No completed, published randomized controlled human trials exist as of this writing. The evidence base — while large — is animal and in-vitro research. Any supplier implying established human efficacy is overstating the literature.

What does BPC stand for?

Body Protection Compound — the name given to the parent gastric-juice protein from which the 15-amino-acid sequence was derived in the Sikiric laboratory's research program.

Why is BPC-157 studied for tendon specifically?

Tendon is poorly vascularized, which limits repair. Research models describe BPC-157 engaging angiogenesis and fibroblast-migration pathways directly relevant to that bottleneck, making tendon one of its most-studied models.

Is BPC-157 an approved treatment?

No. It is a research compound supplied strictly for qualified in-vitro laboratory use and is not for human or veterinary use.

How is it supplied and verified?

Lyophilized powder in sealed vials, identity and purity verified at ≥99% by independent third-party HPLC analysis.

What models dominate the BPC-157 literature?

Gastrointestinal-protection and tendon-repair rodent models dominate, followed by muscle, ligament, and nerve-injury models. Cell-culture mechanistic work (tendon fibroblasts, endothelial cells) underpins the signaling findings.

How should the research material be stored?

Lyophilized vials: frozen at -20°C or below for long-term storage, protected from light and moisture. After reconstitution under sterile laboratory conditions, keep refrigerated at 2–8°C and use within the protocol's validated window.

How the evidence base reads

BPC-157's literature is wide but uniformly preclinical: several hundred published animal and in-vitro studies, largely from one research group and its collaborators, with independent mechanistic replication in cell models. There are no completed published human randomized trials. Researchers should weight the literature accordingly — mechanistically rich, clinically unvalidated.

Laboratory handling and stability

For long-term research storage, keep lyophilized vials frozen at -20°C or below, protected from light and moisture; short-term handling at 2–8°C is standard. Reconstitution should be performed only under sterile laboratory conditions with the laboratory-grade solvent specified by the research protocol, and reconstituted material should be kept cold, protected from light, and used within the validated window of the protocol. Record vial lot numbers and retain the certificate of analysis with study records — traceability is a baseline requirement for reproducible work.

Related research in this library

TB-500 · KPV · KLOW Blend

Why BPC-157 draws so much research attention

Three properties make BPC-157 unusually attractive as a research tool. First, stability: derived from a gastric-juice protein, the sequence is unusually resistant to degradation in gastric conditions in models, simplifying experimental design. Second, breadth: few compounds have published data across tendon, GI, muscle, nerve, and vascular models, giving new studies a large reference base. Third, the open questions: with no identified receptor and bidirectional NO-system behavior, BPC-157 still offers genuine mechanistic discovery potential rather than just confirmation work.

Is BPC-157 banned anywhere in research or sport contexts?

BPC-157 appears on the WADA Prohibited List under the unapproved-substances category, which matters for researchers working with athletic populations or samples. Its preclinical-only status is also why responsible suppliers market it strictly as research material.

Form, handling, and verification

BPC-157 is supplied as a lyophilized (freeze-dried) powder in sealed vials, with identity and purity verified at ≥99% by independent third-party HPLC analysis. Lyophilized material should be stored in a cool, dry environment away from light and handled per standard laboratory protocol with appropriate protective equipment.

View BPC-157 research material →

Research Use Only. All materials referenced are supplied strictly for qualified in-vitro laboratory research. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use.